A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
Recruiting · NCT06668103 · Registry updated 2024-12-12Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib | Non-Small Cell Lung Cancer With EGFR Mutation | Recruiting | Phase 2 | 2024-12-12 | NCT06668103 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Abbisko Therapeutics Co, Ltd | 22 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hanhui Cancer Hospital | Hefei | China | 1 |
| Harbin Medical University Cancer Hospital | Harbin | China | 51 |
| Jilin Cancer Hospital | Changchun | China | 24 |
| Shanghai Chest Hospital | Shanghai | China | 31 |
| Union Hospital Tongji Medical College Huzhong University of Science and Techology | Wuhan | China | 2 |